About: Mitoxantrone therapy in rapidly worsening multiple sclerosis     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • The aim of the study was to asses the effect and safety of mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS). Thirty-three patients (10 males, 23 females, mean age 48.5+/-9.9 years) with relapsing remitting and secondary progressive MS were followed. The disability was evaluated using Expanded Disability Status Scale (EDSS). The mean time period from the onset to secondary progressive course of the disease was 9.3+/-9.8 years. Patients, whose disability progression increased by one or more EDSS points per one year, and who did not respond to other therapy, were treated with mitoxantrone. Patients were treated monthly with intravenous administration of mitoxantrone 12 mg/m2 (not exceeding the maximum cumulative dose of 140 mg/m2) and methylprednisolone 1000 mg. Six pulses were administered in each patient. EDSS score was measured at the beginning of the treatment and after twelve months. Disability progression was evaluated.
  • The aim of the study was to asses the effect and safety of mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS). Thirty-three patients (10 males, 23 females, mean age 48.5+/-9.9 years) with relapsing remitting and secondary progressive MS were followed. The disability was evaluated using Expanded Disability Status Scale (EDSS). The mean time period from the onset to secondary progressive course of the disease was 9.3+/-9.8 years. Patients, whose disability progression increased by one or more EDSS points per one year, and who did not respond to other therapy, were treated with mitoxantrone. Patients were treated monthly with intravenous administration of mitoxantrone 12 mg/m2 (not exceeding the maximum cumulative dose of 140 mg/m2) and methylprednisolone 1000 mg. Six pulses were administered in each patient. EDSS score was measured at the beginning of the treatment and after twelve months. Disability progression was evaluated. (en)
Title
  • Mitoxantrone therapy in rapidly worsening multiple sclerosis
  • Mitoxantrone therapy in rapidly worsening multiple sclerosis (en)
skos:prefLabel
  • Mitoxantrone therapy in rapidly worsening multiple sclerosis
  • Mitoxantrone therapy in rapidly worsening multiple sclerosis (en)
skos:notation
  • RIV/00216224:14110/05:00014829!RIV10-MSM-14110___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • Z(MSM0021622404)
http://linked.open...iv/cisloPeriodika
  • 3
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 530403
http://linked.open...ai/riv/idVysledku
  • RIV/00216224:14110/05:00014829
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • multiple sclerosis; immunotherapy; mitoxantrone; EDSS (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • SK - Slovenská republika
http://linked.open...ontrolniKodProRIV
  • [3AFDFB3731F3]
http://linked.open...i/riv/nazevZdroje
  • Bratislavské lekárske listy
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 106
http://linked.open...iv/tvurceVysledku
  • Kadaňka, Zdeněk
  • Štourač, Pavel
  • Benešová, Yvonne
  • Beránek, M.
http://linked.open...n/vavai/riv/zamer
issn
  • 0006-9248
number of pages
http://localhost/t...ganizacniJednotka
  • 14110
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software